Pivekimab Sunirine: A Novel CD123 ADC Showing Promise for BPDCN

Sangeetha Venugopal, MD, MS, discusses pivekimab sunirine (PVEK), a novel CD123-targeting antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm (BPDCN). PVEK showed promising response rates in treatment-naïve BPDCN patients in an early trial and was reasonably well-tolerated without concerning safety signals. Its FDA breakthrough therapy designation in relapsed/refractory BPDCN was based on phase 1 data suggesting good efficacy even after tagraxofusp (TAG). Early trials also support PVEK's potential in CD123+ acute myeloid leukemia, both as monotherapy and when combined with other agents like azacitidine and venetoclax.

EP: 1.Diagnosing Blastic Plasmacytoid Dendritic Cell Neoplasm

EP: 2.BPDCN: A Multidisciplinary Approach to Diagnosis and Treatment

Now Viewing

EP: 3.Pivekimab Sunirine: A Novel CD123 ADC Showing Promise for BPDCN

EP: 4.Advances in Diagnosis and Targeted Therapies for BPDCN from an Expert Dermatopathologist

EP: 5.Emerging CD123-Targeted Therapies for BPDCN: Pivotal Trial Insights and Future Potential

Related Videos